LAVA Therapeutics N.V. (LVTX)

2.6400 -0.1000 (-3.65%) At close: 04:00PM EDT

LAVA Therapeutics N.V.

Yalelaan 62
Utrecht 3584 CM
Netherlands
31 85 016 3100
https://www.lavatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 37

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephen Allen Hurly M.B.A., M.Sc.	CEO, President & Executive Director	N/A	N/A	1968
Mr. Fred M. Powell CPA	Chief Financial Officer	N/A	N/A	1961
Dr. Hans van der Vliet M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	1974
Ms. Amy Garabedian J.D.	General Counsel & Corporate Secretary	N/A	N/A	1976
Mr. Wouter van Hunnik	VP & Head of Human Resources	N/A	N/A	N/A
Dr. Ton Adang Ph.D.	Chief Development Officer	N/A	N/A	1961
Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.	Chief Medical Officer	N/A	N/A	1965

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Corporate governance

LAVA Therapeutics N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.